Abstract
Infectious complications are the leading causes of morbidity and mortality among renal transplant recipients. Hypogammaglobulinaemia may develop as a result of immunosuppressive therapy and is associated with an increasedriskofopportunisticinfectionsparticularlyinthe6month post-transplant period. Rituximab, which is used for antibody-mediatedrejection(AMR),mayalsocontributeto the development of hypogammaglobulinaemia via B-cell depletion. Intravenous immunoglobulin replacement may be beneficial in this setting. With the following case report, weaimtoincreasetheawarenessofopportunisticinfections andseverehypogammaglobulinaemiainrenaltransplantrecipients treated with rituximab for acute AMR.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
